1. Cardiovascular benefits outweigh risks in patients with atrial fibrillation in REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial). (14th October 2021) Authors: Olshansky, B; Bhatt, D; Miller, M; Steg, P G; Brinton, E A; Jacobson, T A; Ketchum, S B; Doyle Jr, R T; Juliano, R A; Jiao, L; Kowey, P; Reiffel, J A; Tardif, J.-C; Ballantyne, C M; Chung, M K Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗